Immix Biopharma Debt

IMMX Stock  USD 1.97  0.32  19.39%   
Immix Biopharma holds a debt-to-equity ratio of 0.002. At this time, Immix Biopharma's Debt To Equity is fairly stable compared to the past year. Debt Equity Ratio is likely to rise to 0 in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 42.8 K in 2024. With a high degree of financial leverage come high-interest payments, which usually reduce Immix Biopharma's Earnings Per Share (EPS).

Asset vs Debt

Equity vs Debt

Immix Biopharma's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Immix Biopharma's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Immix Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Immix Biopharma's stakeholders.
For most companies, including Immix Biopharma, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Immix Biopharma, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Immix Biopharma's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book
3.0876
Book Value
0.823
Return On Assets
(0.57)
Return On Equity
(1.04)
Change To Liabilities is likely to rise to about 1.4 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 2.4 M in 2024.
  
Check out the analysis of Immix Biopharma Fundamentals Over Time.
For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.

Immix Biopharma Bond Ratings

Immix Biopharma financial ratings play a critical role in determining how much Immix Biopharma have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Immix Biopharma's borrowing costs.
Piotroski F Score
3
FrailView
Beneish M Score
(6.25)
Unlikely ManipulatorView

Immix Biopharma Debt to Cash Allocation

As Immix Biopharma follows its natural business cycle, the capital allocation decisions will not magically go away. Immix Biopharma's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Immix Biopharma currently holds 3.72 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Immix Biopharma has a current ratio of 19.14, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Immix Biopharma's use of debt, we should always consider it together with its cash and equity.

Immix Biopharma Total Assets Over Time

Immix Biopharma Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Immix Biopharma uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Immix Biopharma Debt Ratio

    
  0.3   
It appears most of the Immix Biopharma's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Immix Biopharma's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Immix Biopharma, which in turn will lower the firm's financial flexibility.

Immix Biopharma Corporate Bonds Issued

Immix Short Long Term Debt Total

Short Long Term Debt Total

42,750

At this time, Immix Biopharma's Short and Long Term Debt Total is fairly stable compared to the past year.

Understaning Immix Biopharma Use of Financial Leverage

Understanding the structure of Immix Biopharma's debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to Immix Biopharma's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Last ReportedProjected for Next Year
Short and Long Term Debt Total45 K42.8 K
Net Debt-17.5 M-16.6 M
Short and Long Term Debt45 K42.8 K
Short Term Debt45 K42.8 K
Net Debt To EBITDA 1.09  0.57 
Cash Flow To Debt Ratio(36.55)(34.73)
Please read more on our technical analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.